A drug galcanezumab, initially developed as LY2951742, represents the significant advance in migraine treatment. The chemical structure is that of a humanized monoclonal protein, specifically targeting the target. The https://bookmark-template.com/story29032286/galcanezumab-a-deep-dive-into-ly2951742-and-its-chemical-identity